Introduction
Lazerib 80 mg (Lazertinib) is a cutting-edge, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). Manufactured by Everest Pharmaceuticals Ltd. and supplied globally by Onco Solution, this medication is a breakthrough for patients with non-small cell lung cancer (NSCLC). Lazerib is specifically designed to target both the common EGFR mutations and the T790M resistance mutation. It is highly brain-penetrant, making it an effective choice for treating patients whose cancer has spread to the central nervous system.+2
Indications
Lazerib 80 mg (Lazertinib) is indicated for:
- First-line Treatment: Adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 L858R substitution mutations.
- Second-line Treatment: Patients with metastatic EGFR T790M mutation-positive NSCLC who have progressed on or after prior EGFR TKI therapy.
- Combination Therapy: Often used in combination with other monoclonal antibodies (like Amivantamab) for advanced oncology cases.
Pharmacology
Lazertinib, the active ingredient in Lazerib, is an irreversible, oral, third-generation EGFR TKI. It works by binding to the kinase domain of the EGFR protein, effectively blocking the signaling pathways that lead to tumor cell growth and survival. Unlike first-generation inhibitors, Lazertinib is highly selective for mutant forms of EGFR over the “wild-type” (normal) EGFR, which helps reduce side effects like skin rashes and diarrhea. Its ability to cross the blood-brain barrier ensures efficacy against intracranial metastases.+3
Dosage & Administration
Oral Administration for Adults:
- Standard Dose: 240 mg (three 80 mg tablets) taken orally once daily.
- Administration: Tablets should be taken at the same time each day, with or without food.
- Missed Dose: If a dose is missed by more than 12 hours, skip that dose and take the next dose at the scheduled time.
- Note: Dosage may be adjusted by an oncologist based on individual patient tolerance and clinical response.
Drug Interactions
- Strong CYP3A4 Inducers: Avoid co-administration (e.g., Rifampin, Phenytoin) as they can significantly decrease Lazertinib plasma levels.
- Strong CYP3A4 Inhibitors: Use with caution as they may increase the risk of toxicity.
- P-gp Inhibitors: May increase the absorption of Lazertinib.
- Note: Patients should consult their specialist before taking any herbal supplements (like St. John’s Wort) during treatment.
Contraindications
- Hypersensitivity: Known hypersensitivity to Lazertinib or any inactive ingredients in the tablet.
- Severe Hepatic Impairment: Not recommended for patients with significantly compromised liver function without strict medical monitoring.
Side Effects
Patients receiving Lazerib 80 mg may experience:
- Dermatological: Mild rash, dry skin, or paronychia (nail bed inflammation).
- Neurological: Paresthesia (tingling or numbness in extremities).
- Gastrointestinal: Diarrhea, nausea, or decreased appetite.
- Hematological: Anemia or slight decrease in white blood cell counts.
- General: Fatigue, musculoskeletal pain, and headaches.
Pregnancy & Lactation
- Pregnancy: Lazertinib can cause fetal harm. Effective contraception is required during treatment and for several weeks after the final dose.+1
- Lactation: It is unknown if the drug passes into breast milk; therefore, breastfeeding is not recommended during therapy.
Precautions & Warnings
- Interstitial Lung Disease (ILD): Monitor for acute onset of respiratory symptoms (dyspnea, cough, fever). Discontinue if ILD is suspected.
- QT Interval Prolongation: Periodic ECG monitoring and electrolyte checks are advised, especially for patients with pre-existing heart conditions.
- Liver Function: Regular monitoring of ALT, AST, and bilirubin is recommended during the course of treatment.
Use in Special Populations
- Elderly Patients: No specific dose adjustment is usually required, but close monitoring for adverse reactions is necessary.
- Renal Impairment: Use with caution in patients with severe renal disease.
Overdose Effects
Overdose symptoms may include severe gastrointestinal distress or intensified skin reactions. Treatment is symptomatic and supportive.
Storage
- Condition: Store at room temperature (15°C to 30°C).
- Protection: Keep the bottle tightly closed and store in a cool, dry place away from direct sunlight. Keep out of reach of children.
Supplier Information
Onco Solution is a trusted global oncology medicine provider. We specialize in making advanced, life-saving therapies like Lazerib 80 mg accessible to patients and clinics worldwide. For pricing and global shipping, visit www.oncosolution.com.
Manufacturer Information
Lazerib 80 mg is manufactured by Everest Pharmaceuticals Ltd., a premier pharmaceutical manufacturer in Bangladesh dedicated to producing high-quality, specialized oncology and life-saving generic medications.
